As a National Clinic Trials Network Lead Academic Participating Site, we hope to accomplish the following: 1. To provide scientific leadership and intellectual input in the creation of thoughtful, feasible trials to improve the health of cancer patients. We will accomplish this aim through the ongoing participation in clinical trials that spn the spectrum of disease-specific and radiation and surgical oncology; by applying the UNC culture of multidisciplinary care to make NCTN trials stronger and more modern; by leveraging the commitment of junior faculty, who will be the leaders of tomorrow; and by applying health services research in the development of clinical trials, including factors important to clinical outcomes, such as cost effectiveness, delivery of care, and policy. 2. To continue to be strong supporters of Network trials, through our rapidly growing clinical enterprise and robust accrual. We will support this aim by building on our historically strong accrual to CALGB, GOG, and ACOSOG trials and our well-funded and organized infrastructure, and through active participation across the NCTN. 3. To provide opportunities for excellent translational science embedded in NCTN clinical trials. UNC has a long commitment to translational science and has served as reference lab across multiple trials, with substantial (more than $3 million) investment in Next Generation sequencing and genomics; we are well suited to serve as a translational research collaborator for clinical trials in the future.

Public Health Relevance

The UNC Lineberger Lead Academic Participating Site brings together an accomplished group of academic clinical oncologists and faculty from related disciplines, organized into multidisciplinary disease-site groups, to undertake cutting edge clinical research across the spectrum of cancers. The UNC LAPS will commit the staff and professional resources to manage and evaluate these research activities, accrue patients, and share knowledge with the wider research community. This effort will serve to enhance the understanding of cancer progression and treatment, lead to new studies based on information learned, and improve outcomes for patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA180838-04
Application #
9234503
Study Section
Special Emphasis Panel (ZCA1-GRB-P (O1))
Program Officer
Mooney, Margaret M
Project Start
2014-05-07
Project End
2019-02-28
Budget Start
2017-03-01
Budget End
2018-02-28
Support Year
4
Fiscal Year
2017
Total Cost
$454,315
Indirect Cost
$181,176
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Camargo, M Constanza; Bowlby, Reanne; Chu, Andy et al. (2016) Validation and calibration of next-generation sequencing to identify Epstein-Barr virus-positive gastric cancer in The Cancer Genome Atlas. Gastric Cancer 19:676-81
Becker, Marc A; Ibrahim, Yasir H; Oh, Annabell S et al. (2016) Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer. PLoS One 11:e0150564
Basch, Ethan; Rogak, Lauren J; Dueck, Amylou C (2016) Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. Clin Ther 38:821-30
Hatch, Ace J; Sibley, Alexander B; Starr, Mark D et al. (2016) Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Cancer Med 5:2249-60
Freedman, Rachel A; Seisler, D K; Foster, J C et al. (2016) Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). Breast Cancer Res Treat :
Brooks, Samira A; Khandani, Amir H; Fielding, Julia R et al. (2016) Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression. Clin Cancer Res 22:2950-9
Atkinson, Thomas M; Ryan, Sean J; Bennett, Antonia V et al. (2016) The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer 24:3669-76
Abida, Wassim; Milowsky, Matthew I; Ostrovnaya, Irina et al. (2016) Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma. Bladder Cancer 2:111-117
Dickler, Maura N; Barry, William T; Cirrincione, Constance T et al. (2016) Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J Clin Oncol 34:2602-9
Jatoi, Aminah; Muss, Hyman; Allred, Jake B et al. (2016) Social support and its implications in older, early-stage breast cancer patients in CALGB 49907 (Alliance A171301). Psychooncology 25:441-6

Showing the most recent 10 out of 52 publications